RMRyan A. Maddox

Ryan A. Maddox

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryan A. Maddox has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Ermias D. Belay

    Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

    6 shared publications
  • Lawrence B Schonberger

    Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

    3 shared publications
  • Lawrence B. Schonberger

    Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, Georgia

    3 shared publications
  • Yosikazu Nakamura

    Department of Public Health, Jichi Medical University, Shimotsuke, Tochigi, Japan

    2 shared publications
  • A. R. Harvey

    Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

    1 shared publication
  • Aaron T Curns

    †Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication

Latest Publications

  • Kawasaki Disease and Kawasaki Disease Shock Syndrome Hospitalization Rates in the United States, 2006–2018

    by Ryan A. Maddox, Marissa K. Msph Person, Jordan L. Msph Kennedy, Jessica Leung, Joseph Y. Abrams, Dana L. Msph Haberling, Lawrence B. Schonberger, Ermias D. Belay

    Background: Kawasaki disease (KD) is a febrile illness of unknown etiology. Patients with Kawasaki disease shock syndrome (KDSS) may present with clinical signs of poor perfusion and systolic hypotension in addition to typical KD features. The United States Centers for Disease Control and Prevention analyzes and interprets large hospitalization databases as a mechanism for conducting national KD surveillance. Methods: The Kids’ Inpatient Database (KID), the National (Nationwide) Inpatient Sample (NIS), and the IBM MarketScan Commercial (MSC) and MarketScan Medicaid (MSM) databases were analyzed to determine KD-associated hospitalization rates and trends from 2006 to the most recent year of available data. KD and potential KDSS hospitalizations were defined using International Classification of Disease-Clinical Modification codes. Results: For the most recent year, the KD-associated hospitalization rates for children <5 years of age were 19.8 (95% CI: 17.2–22.3, KID: 2016), 19.6 (95% CI: 16.8–22.4, NIS: 2017), 19.3 (MSC: 2018), and 18.4 (MSM: 2018) per 100,000. There was no indication of an increase in KD rates over the time period. Rates of potential KDSS among children <18 years of age, ranging from 0.0 to 0.7 per 100,000, increased; coding indicated potential KDSS for approximately 2.8%–5.3% of KD hospitalizations. Conclusions: Analyses of these large, national databases produced consistent KD-associated hospitalization rates, with no increase over time detected; however, the percentage of KD hospitalizations with potential KDSS increased. Given reports of increasing incidence elsewhere and the recent identification of a novel virus-associated syndrome with possible Kawasaki-like features, continued national surveillance is important to detect changes in disease epidemiology.


  • Prion disease incidence in the United States: 2003–2015

    by Ryan A. Maddox, Marissa K. Person, Janis E. Blevins, Joseph Y. Abrams, Brian S. Appleby, Lawrence B. Schonberger, Ermias D. Belay

    Objective To report the incidence of prion disease in the United States. Methods Prion disease decedents were retrospectively identified from the US national multiple cause-of-death data for 2003–2015 and matched with decedents in the National Prion Disease Pathology Surveillance Center (NPDPSC) database through comparison of demographic variables. NPDPSC decedents with neuropathologic or genetic test results positive for prion disease for whom no match was found in the multiple cause-of-death data were added as cases for incidence calculations; those with cause-of-death data indicating prion disease but with negative neuropathology results were removed. Age-specific and age-adjusted average annual incidence rates were then calculated. Results A total of 5,212 decedents were identified as having prion disease, for an age-adjusted average annual incidence of 1.2 cases per million population (range 1.0 per million [2004 and 2006] to 1.4 per million [2013]). The median age at death was 67 years. Ten decedents were <30 years of age (average annual incidence of 6.2 per billion); only 2 of these very young cases were sporadic forms of prion disease. Average annual incidence among those ≥65 years of age was 5.9 per million. Conclusions Prion disease incidence can be estimated by augmenting mortality data with the results of neuropathologic and genetic testing. Cases <30 years of age were extremely rare, and most could be attributed to exogenous factors or the presence of a genetic mutation. Continued vigilance for prion diseases in all age groups remains prudent.


  • Clinically Unsuspected Prion Disease Among Patients With Dementia Diagnoses in an Alzheimer’s Disease Database

    by Ryan A. Maddox, J. L. Blase, N. D. Mercaldo, A. R. Harvey, L. B. Schonberger, W. A. Kukull, E. D. Belay

    Background: Brain tissue analysis is necessary to confirm prion diseases. Clinically unsuspected cases may be identified through neuropathologic testing. Methods: National Alzheimer’s Coordinating Center (NACC) Minimum and Neuropathologic Data Set for 1984 to 2005 were reviewed. Eligible patients had dementia, underwent autopsy, had available neuropathologic data, belonged to a currently funded Alzheimer’s Disease Center (ADC), and were coded as having an Alzheimer’s disease clinical diagnosis or a nonprion disease etiology. For the eligible patients with neuropathology indicating prion disease, further clinical information, collected from the reporting ADC, determined whether prion disease was considered before autopsy. Results: Of 6000 eligible patients in the NACC database, 7 (0.12%) were clinically unsuspected but autopsy-confirmed prion disease cases. Conclusion: The proportion of patients with dementia with clinically unrecognized but autopsy-confirmed prion disease was small. Besides confirming clinically suspected cases, neuropathology is useful to identify unsuspected clinically atypical cases of prion disease.


  • Recurrent Kawasaki disease: USA and Japan

    by Ryan A Maddox, Robert C Holman, Ritei Uehara, Laura S Callinan, Jodie L Guest, Lawrence B Schonberger, Yosikazu Nakamura, Mayumi Yashiro, Ermias D Belay

    Background: Descriptive epidemiologic studies of recurrent and non‐recurrent Kawasaki disease (KD) may identify other potentially important differences between these illnesses.Methods: Data from the USA and Japan, the Centers for Disease Control and Prevention (CDC) national KD surveillance(1984–2008) and the 17th Japanese nationwide survey (2001–2002), respectively, were analyzed to examine recurrent KD patients <18 years of age meeting the CDC KD case or atypical KD case definition. These patients were compared with non‐recurrent KD patients.Results: Of the 5557 US KD patients <18 years of age during 1984–2008, 97 (1.7%) were identified as having had recurrent KD. Among the US Asian/Pacific Islander KD patients, 3.5% had recurrent KD, which was similar to the percentage identified among KD patients (3.5%) in the Japanese survey. Compared with non‐recurrent KD patients, KD patients [with recurrent KD] were more likely to be older, fulfill the atypical KD case definition, and have coronary artery abnormalities (CAA) despite i.v. immunoglobulin (IVIG) treatment.Conclusions: Differences in the age, race, and frequency of CAA exist between recurrent and non‐recurrent KD patients. The increased association of CAA with recurrent KD suggests that more aggressive treatment strategies in conjunction with IVIG may be indicated for the second episode of KD.


  • Open Access

    Reply to Smyth et al

    by Ryan A. Maddox, Lawrence B. Schonberger, Ermias D. Belay

    Reply to Smyth et al - Volume 35 Issue 7 - Ryan A. Maddox, Lawrence B. Schonberger, Ermias D. Belay

  • Creutzfeldt-Jakob Disease in Recipients of Corneal Transplants

    by Ryan A Maddox, Ermias D Belay, Aaron T Curns, Wen-Quan Zou, Scott Nowicki, Richard G Lembach, Michael D Geschwind, Aissa Haman, Naoshi Shinozaki, Yosikazu Nakamura, et al.

    Creutzfeldt-Jakob disease (CJD) transmission has been documented to occur from the use of corneal grafts. We report 4 cases of CJD with a history of corneal transplantation and assess the frequency of coincidental CJD among corneal transplant recipients. Medical records and eye bank documents were reviewed. Genetic and neuropathologic tests on available specimens were performed at the National Prion Disease Pathology Surveillance Center. Statistical analyses were used to determine the expected number of coincidental CJD cases among the US population with a history of corneal transplantation. Four CJD decedents with histories of corneal transplantation were identified: 3 from the United States and 1 from Japan. The time from transplant to onset of CJD symptoms ranged from 2 years, 11 months to 18 years. Available eye bank records did not suggest evidence of neurologic illness in the donors. Using corneal transplantation and CJD death data from 1990 through 2006, statistical analyses suggest that a case of coincidental sporadic CJD will occur among the population of corneal transplant recipients approximately every 1.5 years. It is likely that these 4 recipients of transplanted corneas had sporadic CJD. Because of the many corneal transplantations performed each year in the United States, occasional cases of sporadic CJD in this population are expected.


  • Creutzfeldt–Jakob disease among American Indians and Alaska Natives in the United States

    by R. A. Maddox, R. C. Holman, E. D. Belay, J. E. Cheek, K. L. Yorita, L. B. Schonberger

    The occurrence of Creutzfeldt–Jakob disease (CJD) among American Indians and Alaska Natives in the United States was evaluated using national multiple cause-of-death data and medical information obtained from state health departments. Twelve CJD deaths were identified for 1981 through 2002, and the average annual age-adjusted death rate was 0.47 per million population. This rate was significantly lower than that for whites and similar to the rate for African Americans.


  • Kawasaki Syndrome in Georgia, USA, 1997-1998: Evaluating the Usefulness of Hospital Discharge Data for Surveillance

    by Robert C Holman, Robert V Gibbons, Ermias D Belay, Umesh D Parashar, Ryan A Maddox, Kenneth E Powell, Lawrence B Schonberger